INSERM researchers develop vaccines against Crohn’s disease and obesity

Researchers at France’s National Institute of Health and Medical Research (INSERM) have just detailed the process of their newly developed vaccine to help treat inflammatory diseases such as Crohn’s disease and metabolic diseases such as obesity. The key to the effectiveness of vaccines lies in the intestinal flora. If the latter is abnormal, or causes a variety of health-related illnesses. INSERM’s new vaccine seeks to protect the intestinal wall by modifying the bacteria.

INSERM researchers develop vaccines against Crohn's disease and obesity

(Pictured: Wikipedia, via Slash Gear)

Chronic enteritis refers specifically to pain, bleeding, etc., caused by persistent inflammation in the digestive tract, and while some patients have found a way to relieve their diet, others have difficulty controlling their condition, which is where the new INSERM vaccine works.

Past studies have shown that the diversity of the flora is usually low in patients with this type of enteroid disease. And an excess of whiplash protein, or allow bacteria to penetrate the protective mucous membranethat that covers the intestinal wall.

Once this happens, an inflammatory reaction can occur in any animal’s body. Long-term sustainability can even be life-threatening and health-threatening.

INSERM’s new vaccine is designed to stimulate the production of anti-whiplash protein antibodies that are naturally present in the protective mucus layer, ultimately suppressing the bacteria behind the whiplash protein.

The researchers tested new immunization methods in mice. It was found that whiplash protein was not detected in the intestinal mucosa of the subjects, which meant that the bacteria that expressed the protein were lower, which proved to be effective in protecting.

In mice fed on a high-fat diet, the same vaccine was used to test their effecton on metabolic disorders in mice. The results showed that no obesity occurred in the subject group, while the control group was obese.

Looking ahead, INSERM hopes the new program will be used for test ingress treatments for patients with diabetes, obesity, IDB, etc.

Add a Comment

Your email address will not be published. Required fields are marked *